Nathan Denlinger
Ohio State University
36 Papers
23 Citations
Nathan Denlinger is an academic researcher from Ohio State University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 10 publications. Previous affiliations of Nathan Denlinger include James Cancer Hospital.
Chat about Author
Papers
Recent Advances and Challenges in Cancer Immunotherapy
TL;DR: The current landscape of immuno-oncology research is discussed, with a focus on elements that influence immunotherapeutic outcomes, and the role of the immunosuppressive cells within the tumor microenvironment in regulating antitumor immunity is highlighted.
66
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
Joanna C. Zurko,Jeremy Ramdial,Mazyar Shadman,Saira Ahmed,A. Szabo,Lorenzo Iovino,Ana Alarcon Tomas,Craig S. Sauter,Miguel-Angel Perales,Nirav N. Shah,Utkarsh Acharya,Caron A. Jacobson,Robert J. Soiffer,Trent P Wang,Krishna V. Komanduri,Samantha Jaglowski,Adam Kittai,Nathan Denlinger,Madiha Iqbal,Mohamed A. Kharfan-Dabaja,Ernesto Ayala,Julio C. Chavez,Michael D. Jain,Frederick L. Locke,Yazeed Samara,Lihua E. Budde,Matthew Mei,Alexandra Della Pia,Ted Feldman,Nausheen Ahmed,Ryan Jacobs,Nilanjan Ghosh,Bhagirathbhai Dholaria,Olalekan O. Oluwole,Brian T. Hess,Ayesha A. Hassan,Vaishalee P. Kenkre,Patrick M. Reagan,Farrukh T. Awan,Yago Nieto,Mehdi Hamadani,Alex F. Herrera +41 more
TL;DR: A multicenter retrospective study assessing the safety, toxicities, and outcomes of alloHCT in LBCL patients following CAR-T failure finds that one-year overall survival, progression- free survival, and graft-versus-host disease-free relapse-free survival were 59, 45, and 39% respectively.
57
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
Joanna C. Zurko,Imran Nizamuddin,Narendranath Epperla,Kevin A. David,Jonathon B. Cohen,Tamara K. Moyo,Thomas A Ollila,Brian T. Hess,Ishan Roy,Robert Ferdman,Jieqi Liu,Sayan Mullick Chowdhury,Jason T. Romancik,Rahul S. Bhansali,Elyse I. Harris,M F Sorrell,Rebecca H. Masel,Adam Kittai,Nathan Denlinger,Audrey M. Sigmund,Lindsey Fitzgerald,Carlos Galvez,Shuo Ma,Jane N. Winter,Barbara Pro,Leo I. Gordon,Alexey V. Danilov,Deborah M. Stephens,Nirav N. Shah,Vaishalee P. Kenkre,Stefan K. Barta,Pallawi Torka,Geoffrey Shouse,Reem Karmali +33 more
TL;DR: A multicenter retrospective analysis of patients treated with CAR-T for aggressive B-NHL between 2015-2021 provided a benchmark for future clinical trials in patients with progression post-CAR-T, an unmet clinical need.
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
Jonathan E. Brammer,Zachary Braunstein,Aashish Katapadi,Kyle Porter,Michael Biersmith,Avirup Guha,Sumithira Vasu,Vedat Yildiz,Sakima A. Smith,Benjamin Buck,Devin Haddad,Richard J. Gumina,Basem M. William,Sam Penza,Ayman Saad,Nathan Denlinger,Ajay Vallakati,Ragavendra R. Baliga,Raymond L. Benza,Philip Binkley,Lai Wei,Mason Mocarski,Steven M. Devine,Samantha Jaglowski,Daniel Addison +24 more
TL;DR: Among adult lymphoma patients, moderate toxicity manifest as grade 2 CRS after CAR-T infusion may associate with favorable clinical outcomes, and further studies are needed to confirm these findings.
20
Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
Lindsey Fitzgerald,Adam Kittai,Loretta J. Nastoupil,Alexandra Waller,Caron A. Jacobson,Anna Saucier,Manali Kamdar,Janet Spradley,Nathan Denlinger,Jonathan Chipman,Boyu Hu +10 more
TL;DR: This data indicates that conventional chemotherapy for R/R DLBCL patients treated with CAR-T has drastically improved outcomes, but the results are still limited in terms of absolute survival and morbidity.
18